Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus Enzalutamide in mCRPC
NCT03016312Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of atezolizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Roche. Started Jan 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03016312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03016312.